UNSPSC 51263157: Bupranolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H22ClNO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DTC2G3GDPL, chemically known as 2-propanol, 1-tert-butylamino-3-(6-chloro-m-tolyloxy)-, hydrochloride but more generally known as bupranolol hydrochloride, which bears US NIH Compound Identifier 27072. European Medicines Agency schedules Bupranolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00903MIG.

Most nations, for tariff and trade purposes, schedule bupranolol hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, BUPRANOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCC(C(C1)OCC(CNC(C)(C)C)O)CL.CL.

UNSPSC 51263157 Bupranolol hydrochloride is a Commodity code in the pharmaceutical and chemical products taxonomy, but recent state and local solicitations tagged under this code do not match its narrow scope. The Seminole County, Florida IFB and the Texas Health and Human Services Commission RFI both involve pharmaceutical procurement — naloxone, drug deactivation systems, and pharmacy benefit management — yet neither specifically targets bupranolol hydrochloride, a beta-blocker cardiovascular medication. The code appears to show minimal relevant recent activity aligned with its stated product line.

Seminole County Community Health Building is the standout issuing body in the available records, soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually through IFB 60459723LAS with a response deadline of July 26, 2023. Texas HHS issued an exploratory RFI (HHS0017013, closed April 3, 2026) on direct-to-manufacturer prescription programs, seeking vendor capabilities for self-insured employee group health plans and state agencies operating outside traditional pharmacy benefit manager and group purchasing organization channels. Florida and Texas are the only jurisdictions represented in recent postings. The mismatch between the commodity code's stated product (bupranolol hydrochloride) and the actual solicitation scope (naloxone, drug deactivation, pharmacy program infrastructure) suggests this code either receives sparse activity or is infrequently used for state and local pharmaceutical procurement in practice.